LGM Pharma

Bardoxolone methyl

CAS No: 218600-53-4

Bardoxolone methyl

LGM Pharma is a Bardoxolone methyl 218600-53-4 active pharmaceutical ingredient supplier distributor, based in the USA.

Questions? Call our customer API support number 1-(800)-881-8210.

LGM Pharma offers this active ingredient but not the finished dosage forms.

Inquire about Bardoxolone methyl

Product Details:

CAS No: 218600-53-4
Synonyms: (+)-methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate, 2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid methyl ester, Bardoxolone methyl, CDDO Methyl ester, CDDO-Me, NSC 713200, RTA 402, UNII-CEG1Q6OGU1
Molecular Weight: 505.6947 g/mol
Chemical Formula: C32-H43-N-O4
Assay/Purity: Typically NLT 98%
IUPAC Name: Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester
InChl: 1S/C32H43NO4/c1-27(2)11-13-32(26(36)37-8)14-12-31(7)24(20(32)17-27)21(34)15-23-29(5)16-19(18-33)25(35)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3/t20-,22-,24-,29-,30+,31+,32-/m0/s1

Bardoxolone methyl News:

Bardoxolone Methyl 218600-53-4, an Antioxidant Inflammation Modulator, is currently in clinical trials as a potential once a day treatment for those patients suffering from Chronic Kidney Disease (CKD). Developed by Reata Pharmaceuticals, Inc. in partnership with Abbott Laboratories and Kyowa Hakko Kirin, this drug will treat people suffering from CKD due to conditions such as Type 2 Diabetes Mellitus. Both oxidative stress and inflammation occur as a result of CKD, and Bardoxolone Methyl acts as an agent to activate the Nrf2 pathway, thus helping to preserve and aid kidney function in affected patients.


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1).
Any patent infringement and resulting liability is solely at buyer risk.